Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Phase II study evaluates recombinant microplasmin in vitreoretinal disorders

Jan. 21, 2005

Evidence suggests that retinitis pigmentosa may be caused by mutations in the CA4 gene

Jan. 17, 2005

Phase II data on the efficacy of squalamine in wet AMD

Jan. 13, 2005

ISTA launches Vitrase

Jan. 11, 2005

Squalamine selected for CMA Pilot 2 program

Jan. 10, 2005

Macugen approved for neovascular AMD

Dec. 21, 2004

Alcon completes NDA filing for Retaane

Dec. 21, 2004

rEV-131 for postcataract surgery impresses in preclinical study

Dec. 20, 2004

Zylet receives FDA approval

Dec. 17, 2004

Retisert NDA accepted for review

Dec. 17, 2004

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.